Diego Teyssonneau

Bordeaux, France

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 16 publications

Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.

Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study.

Journal: Clinical genitourinary cancer

Published: September 29, 2025

Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancer.

Toxicities of novel androgen receptor pathway inhibitor targeted therapies in advanced prostate cancer.

Journal: Current opinion in urology

Published: September 19, 2025

Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside.

Tertiary lymphoid structures and cancer immunotherapy: From bench to bedside.

Journal: Med (New York, N.Y.)

Published: September 30, 2024

Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials.

Concomitant chemotherapy in trimodal treatment of patients with muscle invasive bladder cancer: A systematic review of prospective trials.

Journal: Critical reviews in oncology/hematology

Published: July 24, 2024

Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response.

Analysis of PD1, LAG3, TIGIT, and TIM3 expression in human lung adenocarcinoma reveals a 25-gene signature predicting immunotherapy response.

Journal: Cell reports. Medicine

Published: April 18, 2024

Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide study.

Health literacy and the use of digital tools in older patients with cancer and their younger counterparts: A multicenter, nationwide study.

Journal: Patient education and counseling

Published: March 14, 2024

Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.

Short-term Darolutamide (ODM-201) Concomitant to Radiation Therapy for Patients with Unfavorable Intermediate-risk Prostate Cancer: The Darius (AFU-GETUG P15) Phase 2 Trial Protocol.

Journal: European urology oncology

Published: February 14, 2024

PARP inhibitors in prostate cancers, is it time for combinations?

PARP inhibitors in prostate cancers, is it time for combinations?

Journal: Therapeutic advances in medical oncology

Published: December 06, 2023

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.

Gastrointestinal metastases in renal cell carcinoma: A retrospective multicenter GETUG (Groupe d'Étude des Tumeurs Uro-Génitales) study.

Journal: European journal of cancer (Oxford, England : 1990)

Published: November 09, 2023

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.

PARP Inhibitors as Monotherapy in Daily Practice for Advanced Prostate Cancers.

Journal: Journal of clinical medicine

Published: February 04, 2022

Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.

Cabazitaxel multiple rechallenges in metastatic castration-resistant prostate cancer.

Journal: Cancer medicine

Published: April 23, 2021

Prostate cancer and PARP inhibitors: progress and challenges.

Prostate cancer and PARP inhibitors: progress and challenges.

Journal: Journal of hematology & oncology

Published: December 14, 2020

Showing 1-12 of 16

Last Updated: 09/26/2026